Press Release

Abemaciclib, marketed as Verzenio, is a key targeted therapy in oncology that continues to expand its clinical and regulatory footprint, particularly in hormone receptor-positive (HR+), human epidermal growth factor receptor

May 5, 2026

Abaloparatide market is witnessing steady growth, driven by increasing awareness and diagnosis of osteoporosis in both postmenopausal women and men, along with rising demand for anabolic bone-building therapies. Abaloparatide, a

May 5, 2026

Abacavir market continues to show steady pharmaceutical and regulatory activity, primarily driven by its use in HIV-1 treatment regimens, especially in pediatric and fixed-dose combination therapies. Recent developments from 2024

May 5, 2026

18 Beta-Glycyrrhetinic Acid market is gaining increasing attention, driven by its expanding therapeutic potential in antiviral and oncology-focused applications. Although this bioactive compound has not yet reached the stage of

May 5, 2026

16-Alpha-Hydroxyprednisolone is evolving in line with broader pharmaceutical quality and compliance trends. While there have been no direct FDA approvals or clinical breakthroughs specifically for this corticosteroid intermediate in 2024–2026,

May 5, 2026

7-ethyl-10-hydroxycamptothecin (SN38), the active metabolite of irinotecan used in colorectal cancer therapy, is witnessing steady growth driven by increasing cancer prevalence and continuous advancements in oncology drug delivery systems. SN38

May 5, 2026

4-Phenyl Butyric Acid market is witnessing steady scientific and pharmaceutical interest, primarily driven by its evolving role in metabolic disorders, neurodegenerative diseases, and viral research applications. Recent developments from 2025

May 5, 2026

How can we help you?

Reach out to discuss how our team can help your business achieve real results.